FUJI LATEX CO., LTD.
5199・Standard Market・Rubber Products
Medical Devices Business
Segment responsible for the manufacturing and sale of rubber-based medical devices such as condoms and probe covers
| Period | Current | Previous | Change |
|---|---|---|---|
| Net sales | ¥2,128 million | ¥2,526 million | ↓ |
| Segment profit | ¥59 million | ¥8 million | ↑ |
| Segment assets | ¥2,848 million | ¥3,535 million | ↓ |
| Depreciation | ¥106 million | ¥104 million | — |
| Impairment loss | ¥146 million | ¥61 million | ↑ |
| Capital expenditures | ¥41 million | ¥43 million | — |
Business Details
Fuji Latex Co., Ltd. manufactures and sells rubber products including medical devices, while its subsidiary Fuji Life Co., Ltd. is mainly responsible for selling the Company's products. The segment consists of the core Healthcare division (diagnostic reagents, etc.) and the Medical division (probe covers, etc.). The condom manufacturing business completed integration from the Tochigi Plant to the Tochigi Chizuka Plant in June 2025, and is establishing itself as a core hub for medical and daily-use rubber products centered on dipping technology.
Recent Overview
Despite a decline in revenue, the segment maintained profitability for the third consecutive year, with cost structure improving following completion of plant integration
Net sales for the Medical Devices Business in FY2026 (ending March 2026) were ¥2,128 million, a decrease of ¥398 million (-15.8%) year on year. The main cause was the disappearance of sales following the halt in condom manufacturing, although the Healthcare Products group, centered on diagnostic reagents, trended favorably. On the profit side, improvement in the production cost structure resulting from the relocation of the Healthcare division's plant exceeded the negative profit impact of the sales decline, and segment profit was ¥59 million, an increase of ¥51 million (682.6%) year on year, marking profitability for the third consecutive year. On the other hand, an impairment loss of ¥146 million was recorded in connection with the plant relocation and integration. Integration of the Tochigi Plant into the Tochigi Chizuka Plant was completed in June 2025.
Key Products
Growth Drivers
- Expected increase in revenue from higher sales of Medical products (probe covers, etc.) to overseas markets
- Establishment of a core hub for medical and daily-use rubber products centered on dipping technology, following completion of integration into the Tochigi Chizuka Plant
- Continued improvement in production cost structure and reduction of cost ratio through the Healthcare division's plant relocation
- Strengthening of technological capability and product development capability through optimization of human resources via unification of development sites
- Medium-term cost reduction through automation of manufacturing equipment and diversification of raw material procurement
Risks
- Structural and permanent shrinkage of sales scale due to the halt in condom manufacturing (revenue decreased 15.8% year on year)
- Outlook for increased revenue but decreased profit for the Medical Devices Business as a whole (FY2027, ending March 2027) due to increased costs for reorganizing the production system associated with integration into the Tochigi Chizuka Plant
- Structural shrinkage of the domestic healthcare market due to the declining birthrate and aging population
- Risk of reduced production efficiency and incurrence of temporary costs during the process of plant relocation and integration
- Risk that delays in launching new product groups will result in insufficient compensation for the revenue decline following the halt in condom manufacturing
Last updated: June 23, 2026